FilingSEC EDGAR8-K
Keros Therapeutics Initiates Phase 2 Clinical Trial Dosing for Rinvatercept in DMD
· SEC accepted
StagePhase 2
Filing content
Keros Therapeutics has dosed the first patient in its Phase 2 clinical trial of rinvatercept for Duchenne muscular dystrophy (DMD), with initial data expected in the first half of 2027.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…